SCHEMBL655632

SCHEMBL655632

Clc1ccc(NC2CCNCC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.58
HTR6 P50406 5/20 0.54
IKBKB O14920 1/20 0.51
HTR1A P08908 2/20 0.45
HTR1D P28221 2/20 0.45
HTR1B P28222 2/20 0.45
HTR2C P28335 2/20 0.45
HTR7 P34969 2/20 0.45
HTR2B P41595 2/20 0.45
HTR3A P46098 1/20 0.44
PLK4 O00444 1/20 0.42
FPR2 P25090 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
P2RX7 Q99572 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15566720 0.98 POLB (0.56) POLBHTR6IKBKBHTR1AHTR1D
SCHEMBL3043147 0.90 POLB (0.49) POLBHTR6IKBKBHTR1AHTR1D
SCHEMBL6216444 0.89 POLB (0.50) POLBHTR6IKBKBHTR3APLK4
Hydrochloric Acid SCHEMBL3040514 0.88 HTR6 (0.49) POLBHTR6IKBKBHTR1AHTR1D
Hydrochloric Acid SCHEMBL10370600 0.87 POLB (0.49) POLBHTR6IKBKBHTR3APLK4
SCHEMBL668906 0.85 POLB (0.68) POLBHTR6FPR2PROKR1ROCK2
SCHEMBL11808670 0.85 POLB (0.68) POLBHTR6FPR2PROKR1ROCK2
Hydrochloric Acid SCHEMBL1919158 0.83 POLB (0.66) POLBHTR6FPR2PROKR1ROCK2
SCHEMBL18855421 0.81 POLB (0.63) POLB
SCHEMBL1844312 0.80 ITK (0.48) POLBHTR6HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230298758-A1 Systems and Methods for Evaluating Gestational Progress and Applications Thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-09-21 US claimed
EP-4241285-A1 SYSTEMS AND METHODS FOR EVALUATING GESTATIONAL PROGRESS AND APPLICATIONS THEREOF The Board of Trustees of the Leland Stanford Junior University (US) 2023-09-13 EP claimed
WO-2022099319-A1 SYSTEMS AND METHODS FOR EVALUATING GESTATIONAL PROGRESS AND APPLICATIONS THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYAN (US) 2022-05-12 WO claimed
EP-4472963-A1 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. (US) 2024-12-11 EP disclosed
CN-118946556-A DGK targeting compounds and uses thereof 阿维纳斯运营公司 2024-11-12 CN disclosed
US-12054474-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-08-06 US disclosed
US-20230298758-A1 Systems and Methods for Evaluating Gestational Progress and Applications Thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-09-21 US disclosed
EP-4241285-A1 SYSTEMS AND METHODS FOR EVALUATING GESTATIONAL PROGRESS AND APPLICATIONS THEREOF The Board of Trustees of the Leland Stanford Junior University (US) 2023-09-13 EP disclosed
WO-2023150186-A1 DGK TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2023-08-10 WO disclosed
US-20230073334-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2023-03-09 US disclosed
US-11512066-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-11-29 US disclosed
US-4225606-A ANTIARRHYTHEMIA AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1980-09-30 US disclosed
US-4208418-A ANTIARRHYTHMIA JANSSEN PHARMACEUTICA N.V. (BE) 1980-06-17 US disclosed
US-4198411-A ANTIARRHYTHMIC AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1980-04-15 US disclosed
US-4197303-A ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE JANSSEN PHARMACEUTICA N.V. (BE) 1980-04-08 US disclosed
US-4197304-A ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1980-04-08 US disclosed
US-4196210-A ANTIARRHYTHMIA AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1980-04-01 US disclosed
US-4157393-A ANTIARRHYTHMIA AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1979-06-05 US disclosed
US-4151286-A ANTIARRHYTHMIC AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1979-04-24 US disclosed
US-4126689-A ANTIARRHYTHMIA JANSSEN PHARMACEUTICA N.V. (BE) 1978-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230073334-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 POLB 4098/4885HTR6 112/4885IKBKB 2985/4885
US-12054474-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 POLB 4098/4885HTR6 112/4885IKBKB 2985/4885
US-11512066-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 POLB 4228/4885HTR6 118/4885IKBKB 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.